Edition:
United Kingdom

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

3.60USD
13 Dec 2017
Change (% chg)

$-0.20 (-5.26%)
Prev Close
$3.80
Open
$3.76
Day's High
$3.76
Day's Low
$3.57
Volume
10,465
Avg. Vol
17,916
52-wk High
$9.38
52-wk Low
$2.85

Chart for

About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates,... (more)

Overall

Beta: 2.95
Market Cap(Mil.): $28.19
Shares Outstanding(Mil.): 7.83
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL

* TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE

12 Dec 2017

BRIEF-Tonix Pharmaceuticals Q3 loss per share $0.77

* Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update

07 Nov 2017

BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya

* Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD

17 Oct 2017

BRIEF-Tonix Pharmaceuticals enters into purchase agreement, registration rights agreement with Lincoln Park Capital Fund

* On Sept. 28 co entered into purchase agreement, registration rights agreement with Lincoln Park Capital Fund LLC

29 Sep 2017

BRIEF-Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya

* Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya® (cyclobenzaprine hcl sublingual tablets) Source text for Eikon: Further company coverage:

14 Sep 2017

BRIEF-Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors

* Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors Source text for Eikon: Further company coverage:

14 Sep 2017

BRIEF-Tonix Pharmaceuticals presents additional phase 2 clinical results, ongoing phase 3 trial design of Tonmya at 2017 Military Health System Research Symposium

* Tonix Pharmaceuticals presented additional phase 2 clinical results in military-related PTSD and design of ongoing phase 3 trial at the 2017 Military Health System Research Symposium

29 Aug 2017

BRIEF-Tonix Pharmaceuticals to present at Military Health System Research Symposium

* Tonix Pharmaceuticals to present additional phase 2 clinical results and design of ongoing phase 3 trial in military-related ptsd at the 2017 military health system research symposium Source text for Eikon: Further company coverage:

21 Aug 2017

BRIEF-Tonix Pharmaceuticals Holding reports Q2 loss per share $0.65

* Tonix Pharmaceuticals reports second quarter 2017 financial results and provides programs update

14 Aug 2017

BRIEF-Tonix Pharmaceuticals files for a mixed shelf of up to $150 mln

* Tonix Pharmaceuticals Holding Corp files for a mixed shelf of up to $150 million - SEC filing‍​ Source text: (http://bit.ly/2vX1sM0) Further company coverage:

11 Aug 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $142.89 +0.29
Pfizer Inc. (PFE.N) $36.64 +0.06
Novartis AG (NOVN.S) CHF83.65 -0.20
AstraZeneca plc (AZN.L) 4,934.50 +9.50
GlaxoSmithKline plc (GSK.L) 1,311.00 -3.00

Earnings vs. Estimates